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Abstract
Androgen deprivation therapy (ADT) is used widely as part of a combined modality for the treatment of prostate cancer. However, ADT has
also been associated with the development of cardiometabolic complications that can increase mortality from cardiovascular events. There is
emerging evidence to suggest that ADT-related cardiometabolic risk can be mitigated by diet and lifestyle modiﬁcation. While the clinical
focus for a nutritional approach for achieving this effect is unclear, it may depend upon the timely assessment and targeting of dietary changes
to the speciﬁc risk phenotype of the patient. The present review aims to address the metabolic origins of ADT-related cardiometabolic risk,
existing evidence for the effects of dietary intervention in modifying this risk, and the priorities for future dietary strategies.
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Introduction: prostate cancer: prevalence, risk factors
and treatments
Prostate cancer is the most common cancer in men, affecting
1·1 million men worldwide in 2012. In the same year, there were
47 300 new cases of diagnosed prostate cancer, and 10 800 deaths
from the disease in the UK(1). While there are no clear modiﬁable
risk factors for prostate cancer, family history, diet and lifestyle and
ageing have all been linked to its development, with 54% of men
diagnosed in the UK being over 70 years of age. Prostate cancer
may be classiﬁed as an adenocarcinoma of the prostate gland
which can progress from a relatively normal, low-grade prostatic
intra-epithelial neoplasm to a high-grade metastatic cancer, with
metastases occurring typically in the seminal vesicles, bladder and
bones of the pelvis, upper legs and lower spine. The progression
of prostate cancer is typically slow, earning it the reputation of
being a cancer that men die ‘with’, rather than ‘from’, but there are
subtypes of the disease that are aggressive and develop rapidly.
Prostate cancer is also associated with a high rate of recovery, with
84% of men in the UK surviving for 10 years or longer after
diagnosis(2).
The growth and function of the prostate is heavily inﬂuenced
by androgens, and chieﬂy testosterone, which plays a key role
in promoting tumour growth. Hence, effective anti-cancer
therapy for locally advanced disease employs systematic
approaches to reduce exposure to testosterone by the surgical
removal of the testes that produce 90% of the hormone
(orchiectomy), or by the administration of drugs that suppress
the production of testosterone (androgen deprivation therapy;
ADT). These approaches are used in combination with localised
treatments that include brachytherapy or external beam radio-
therapy. ADT includes anti-androgen drugs that act at the level
of the testes, and gonadotrophin-releasing hormone (GnRH)
agonists and antagonists, which suppress the production of
testosterone through the hypothalamic–pituitary–gonadal axis.
While ADT is highly effective as a systemic treatment as part of
combined modality therapy, and has been proven to reduce
cancer-speciﬁc mortality, its use, and speciﬁcally the use of
GnRH agonists, has been associated with the co-morbidity of
increased risk of CVD(3,4). This CVD risk is characterised by
increased cardiometabolic abnormalities which have a rapid
onset(5) and underlie an increased prevalence of premature
cardiac events such as myocardial infarction, chronic heart
failure and stroke in prostate cancer patients within 6 months
after ADT has commenced(6–8). While clinical recognition of an
association between ADT and increased risk of cardiac events
comes in the form of contraindications on ADT drug labels, and
the United States Food and Drug Administration’s guidelines for
the management and targeting of ADT in prostate cancer
patients in clinical practice(9), evidence for a causal relationship
between ADT and CVD mortality remains contentious. Reasons
for this include confounding of the evidence by the advanced
age of patients, cross-cultural differences in response to ADT,
and general lack of data from randomised controlled trials
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(RCT), all of which have increased uncertainty as how best to
reverse ADT-related cardiometabolic risk. This review examines
the origins and underlying pathophysiology of ADT-related
cardiometabolic risk, and asks whether existing deﬁnitions of
the metabolic syndrome (MetS) under-report cardiometabolic
risk for men with prostate cancer, and if this risk could be
mitigated through dietary intervention.
Evidence that androgen deprivation therapy increases CVD
morbidity and mortality; explanations for the inconsistency
between observational studies and randomised controlled trials
Keating et al.(10) and others(11) were amongst the ﬁrst to show
that ADT, and speciﬁcally GnRH agonists, increased risk of
incident diabetes and CVD (adjusted hazard ratios 1·44 and
1·16, respectively), and the cardiac events of myocardial
infarction and sudden cardiac death (adjusted hazard ratios 1·11
and 1·16, respectively). These ﬁndings were soon corroborated
by further primary studies, and a highly publicised meta-
analysis of observational prospective cohort studies that
showed GnRH agonists to be associated, unequivocally, with an
increased risk of fatal and non-fatal CVD(12). These associations
have been linked to the adverse effects of ADT on body
composition, insulin sensitivity and other cardiometabolic risk
factors described below(6), and also to the speciﬁc effects of
GnRH agonists in precipitating cardiac events by promoting
vascular dysfunction(13–15) and destabilising atherosclerotic
plaque(16). Nevertheless, RCT have generally failed to
substantiate a direct, and thus causal, link between ADT/GnRH
agonists and cardiac mortality(17–21) (Fig. 1). One meta-analysis
of RCT identiﬁed several possible confounding factors that could
have contributed to its negative outcome(19). These factors
included failure to record early cardiac events that occur char-
acteristically within 6 to 24 months after ADT has commenced in a
10-year follow-up period, the misdiagnoses of cardiac death as a
clinical endpoint, and the recruitment of men onto RCT who
are healthier than their counterparts in observational studies.
The latter is of special importance because the incidence of
ADT-induced cardiovascular mortality has been shown to be
signiﬁcantly higher in men with pre-existing CVD and/or history
of CVD events(12,22–24). This ﬁnding does not exclude men
without a previous history of CVD, in which GnRH agonists are
also associated with premature cardiac events(25), but has led to a
consensus of opinion that all future RCT should stratify patients
according to cardiac co-morbidity at baseline. It is also note-
worthy that observational, prospective cohort studies produce
evidence for associations between external factors or treatments
and disease outcomes, but not evidence for causality which
requires a higher level of evidence, from RCT.
How do the origins and characteristics of androgen
deprivation therapy-related cardiometabolic risk differ
from classic metabolic syndrome?
Classic metabolic syndrome
Cardiometabolic risk can be deﬁned as a constellation of
metabolic risk factors that increase the risk of developing and
dying prematurely from CVD(26). These factors provide the
deﬁning criteria for the MetS, which originates primarily from
an imbalance between energy intake and expenditure that
promotes the accumulation and long-term storage of excess
body fat in subcutaneous adipose tissue (SAT) and visceral
adipose tissue (VAT) and ectopic sites. This increased adiposity
also provides an aetiological link between the MetS and many
cancers(27,28), which explains the high prevalence of the MetS in
many cancer survivors(29).
The various components of the MetS are expressed in a
heterogeneous fashion between individuals, and for this reason
the syndrome has many deﬁnitions, which vary according to the
emphasis placed on one or more components(30). All deﬁnitions
consist of at least ﬁve principal components, three of which
should be expressed to qualify as having the MetS. These are
central adiposity (increased waist circumference), mild hyper-
tension, hyperglycaemia, dyslipidaemia and insulin resistance.
While vascular dysfunction, as marked by a loss of endothelial
vasodilation capacity and elasticity or stiffening of larger
vessels, is not one of the principal components, it has been
described as an integrated marker of cardiometabolic risk and
early prerequisite of atherosclerosis that develops under the
combined inﬂuence of other risk factors. The expression of
abnormalities in glucose and lipid metabolism is particularly
marked in the postprandial phase. This applies especially to the
impaired removal of plasma TAG, the time course of which can
take over 6 h after a fat-containing meal(31). This extended time
interval overlaps naturally with the frequency of food intake
and absorption of dietary fat, placing most healthy individuals
in a postprandial state to some degree throughout the day and
during sleep.
There are marked ethnic and cultural differences in how the
type and distribution of body fat contributes to the development
and expression of cardiometabolic risk. The accumulation of
deep, VAT is a major prerequisite for the development of car-
diometabolic risk and diabetes in white Caucasians and South
Asians, and other ethnic groups who adopt and adapt to a
Westernised diet and inactive lifestyle(32). Possible explanations
for why VAT should be so closely linked to cardiometabolic risk
are that adipocytes in VAT express greater insulin resistance
and higher rates of intracellular lipolysis that elevates serum
levels of NEFA that can promote further insulin resistance. VAT
is also in close proximity to key metabolic organs like the
liver and pancreas, and produces adipokines that confer a pro-
inﬂammatory phenotype on this type of adipose tissue(33).
In contrast, the anatomically more superﬁcial SAT is believed
to have a role in acting as a reservoir or ‘fat sink’ to protect
peripheral tissues and the viscera from being overloaded with
fat(34). As such, the variable capacity of SAT to either retain
or release fat may be a major determinant of preventing or pro-
moting the accumulation of visceral and ectopic fat, respectively.
Interestingly, these determinants of classic MetS may not be the
same progenitors of ADT-related cardiometabolic risk.
Androgen deprivation therapy-related cardiometabolic risk
ADT-related cardiometabolic risk shares several of the compo-
nents of classic MetS – insulin resistance, dyslipidaemia, mild
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hypertension and vascular dysfunction(13,35) – but is also distinct
from the latter as it develops more rapidly from a single
metabolic cause, which is the deﬁciency or relative absence of
testosterone. The pathophysiological effects of testosterone
deﬁciency are of fundamental importance to the unique
expression of ADT-induced cardiometabolic risk. At a mole-
cular level, testosterone deﬁciency alters the pattern of cell
differentiation, so that pluripotent stem cells develop into sub-
cutaneous adipocytes rather than skeletal muscle myocytes(36).
This effect underlies the earliest adverse effect of ADT on body
composition, which is characterised by a pronounced loss of
skeletal muscle (sarcopenia)(37) and accumulation of body fat.
The latter is marked by the speciﬁc accumulation of SAT within
3 months of commencing ADT, as distinct from VAT in classic
MetS(38) (Fig. 2). This has been followed within 6–12 months
after commencing ADT in cohort studies by the development of
cardiometabolic risk factors and signiﬁcant increase in the onset
of premature cardiac events (for example, myocardial infarc-
tion, stroke) in some(6–8), but not other studies(17,18,21,39,40). One
notable feature of ADT that differs from classic MetS is the
preservation or even elevation of serum HDL. However, the
high incidence of premature cardiac events on ADT suggests
that any cardioprotective effects of HDL may be offset by the
adverse effects of ADT on other CVD risk factors. Evidence for
the effects of ADT on vascular function in humans has been
mixed, with reports of increased arterial stiffness and loss
of endothelial cell function in some studies(13–15), but not in
others(35,41). There is evidence, exclusively from animal models,
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Source
D’ Amico et al. (2008) (DFCI 95–096)(96)
Messing et al. (2006) (ECOG/EST 3886)(97)
Bolla et al. (2010) (EORTC 22863)(98)
Schröder et al. (2009) (EORTC 30846)(99)
Studer et al. (2006) (EORTC 30891)(100)
Efstathiou et al. (2009) (RTOG 85-31)(39)
Roach et al. (2008) (RTOG 86-10)(17)
Denham et al. (2011) (TROG 96.01)(101)
Overall
Test for heterogeneity: Q = 5.12: P = 0.64; I 2= 0 %
Azoulay et al. (2011) (stroke)(102)
Hu et al. (2012) (pulmonary embolism)(103)
Hu et al. (2012) (peripheral arterial disease)(103)
Jesperson et al. (2014) (MI)(6)
Jesperson et al. (2014) (stroke)(6)
Keating et al. (2006)–SEER (CHD)(10)
Keating et al. (2006)–SEER (MI)(10)
Keating et al. (2010)–Veterans Health Administration (CHD)(104)
Keating et al. (2010)–Veterans Health Administration (MI)(104)
Keating et al. (2010)–Veterans Health Administration (stroke)(104)
Martin–Merino et al. (2011) (MI)(105)
Van Hemelrijck et al. (DVT)(106)
Van Hemelrijck et al. (2010) (pulmonary embolism)(106)
Van Hemelrijck et al. (2010) (arrhythmia)(107)
Van Hemelrijck et al. (2010) (IHD)(107)
Van Hemelrijck et al. (2010) (non-fatal stroke)(107)
Overall (I 2 = 84.7 % P < 0.001)
Favours ADT Favours Control Relative risk
(95 % CI)
1.02 (0.50, 2.09)
3.26 (0.35, 30.2)
1.30 (0.71, 2.38)
0.97 (0.42, 2.23)
0.91 (0.70, 1.18)
0.78 (0.56, 1.10)
1.23 (0.76, 2.01)
0.79 (0.48, 1.31)
0.93 (0.79, 1.10)
1.17 (1.01, 1.34)   6.35
1.29 (1.18, 1.40)   7.56
1.45 (1.37, 1.54)   8.05
1.28 (1.03, 1.58)   4.70
1.25 (1.01, 1.54)   4.86
1.18 (1.11, 1.25)   8.06
1.24 (1.08, 1.42)   6.40
1.59 (1.43, 1.77)   7.13
1.69 (1.37, 2.09)   4.77
1.65 (1.39, 1.96)   5.62
1.34 (0.99, 1.82)   3.20
2.17 (1.79, 2.64)   5.10
1.21 (0.99, 1.48)   5.01
1.16 (1.06, 1.27)   7.42
1.45 (1.36, 1.54)   7.93
1.47 (1.37, 1.58)   7.80
1.38 (1.29, 1.48)   100.00
Relative risk (95 % CI)
0.1 1.0 10
(a)
(b)
0.1 1.0 10
Fig. 1. Androgen deprivation therapy (ADT) and relative risk of CVD mortality in meta-analyses of randomised controlled trials (a) and prospective cohort studies (b).
Data taken from Nguyen et al.(19) and Bosco et al.(12). Values on the far right in (b) are study weights in %. DFCI, Dana-Farber Cancer Institute; ECOG, Eastern
Cooperative Oncology Group; EORTC, European Organisation for Research and Treatment of Cancer; RTOG, Radiation Therapy Oncology Group; TROG, Trans
Tasman Radiation Oncology Group; MI, myocardial infarction; SEER, Surveillance, Epidemiology, and End Results; DVT, deep vein thrombosis.
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that acute ADT promotes inﬂammation, atherosclerosis
and destabilises plaque(16), and that this relates speciﬁcally to
GnRH agonists and not antagonists. A comparison between the
components of classic MetS and ADT-induced cardiometabolic
risk factors is shown in Table 1.
Relevance of sarcopenia and sarcopenic obesity to
cardiometabolic risk
The age-related decline in skeletal muscle mass and function is
deﬁned as sarcopenia, which when superimposed on obesity
gives rise to sarcopenic obesity. Sarcopenia and sarcopenic
obesity have both been related to insulin resistance and
dysglycaemia(42), and more recently to a higher risk of the MetS
in a Korean cohort(43), and are common ﬁndings in response to
ADT(44). From a mechanistic standpoint, insulin resistance is
believed to produce a metabolic milieu that imbalances the
anabolism and catabolism of skeletal muscle protein and leads
to sarcopenia. The subsequent loss of skeletal muscle then
reduces the capacity to store glucose as glycogen, and to a
lesser extent TAG, but also to a decline in the metabolic
capacity to oxidise glucose and fatty acids that will ultimately
promote fat storage. These metabolic events have the potential
to fuel a vicious cycle that increases cardiometabolic risk in
sarcopenic obesity to a greater extent than can be found in
either condition alone. Moreover, ageing will also contribute to
the risk of developing sarcopenia and cardiometabolic risk
through the natural decline of testosterone production, as was
evident in a prospective study from the expression of hyper-
glycaemia and type 2 diabetes at 10, 20 and 30 years before the
development of sarcopenia(45).
Importance of ectopic fat and partitioning of fat between
subcutaneous adipose tissue and visceral adipose tissue
When alcohol can be excluded as a cause of fat accumulation in
the liver, and liver fat exceeds 5% by weight, this condition is
known as non-alcoholic fatty liver disease (NAFLD). Fatty liver
disease (hepatic steatosis) was originally believed to be clini-
cally benign, but has emerged more recently as a critical
determinant of cardiometabolic risk, and prerequisite for the
development of non-alcoholic steatohepatitis (NASH), a more
serious inﬂammatory condition which can progress to end-stage
liver diseases(46). NAFLD has been associated with all of the
components of classic MetS. It has been shown to be responsive
to diet and lifestyle modiﬁcation(47), but its expression in ADT-
related cardiometabolic risk is unknown. While the overﬂow of
stored fat from SAT (‘fat-sink’ theory) provides one possible
origin of fat for VAT and ectopic sites such as the liver, the
extent to which fatty acids from the expanded SAT depot in
ADT may promote fat deposition in the liver and NAFLD is
equally unknown. It is possible that the extent of fat accumu-
lation in the liver could contribute to the variability in the
severity of ADT-related cardiometabolic risk expression
between different individuals (Fig. 3).
Does the metabolic syndrome have clinical utility in the
identiﬁcation and management of androgen deprivation
therapy-related cardiometabolic risk?
CVD risk is known to increase with the number of components
of the MetS(26), but it has been argued that classic MetS has no
diagnostic or prognostic value, since its individual components
are equally or more effective in predicting CVD risk than
combinations of these components(48). Individual cardiometa-
bolic risk factors are also treated clinically in isolation of one
another by drug therapies. Clear differences between ADT and
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Fig. 2. Abdominal MRI before (a) and after (b) androgen deprivation therapy (ADT)(38), showing the accumulation of subcutaneous adipose tissue (SAT), and relative
depletion of visceral adipose tissue (VAT) and loss of skeletal muscle (SM) after ADT.
Table 1. Physical and biochemical characteristics associated with classic
metabolic syndrome and androgen deprivation therapy (ADT)-related
cardiometabolic risk
Classic metabolic syndrome ADT-related cardiometabolic risk
Mild hypertension
Dyslipidaemia
Insulin resistance
Vascular dysfunction
Accumulation of visceral fat
Central adiposity (increased waist
circumference)
Hyperglycaemia
Abnormalities in glucose and lipid
metabolism (impaired clearance
of plasma TAG)
Mild hypertension
Dyslipidaemia
Insulin resistance
Vascular dysfunction
Accumulation of subcutaneous
adipose tissue
Rapidly develops from a single
metabolic cause
Pronounced loss of skeletal muscle
(sarcopenia)
Preservation or elevation of
serum HDL
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classic MetS suggest that the latter may have even less clinical
utility in the identiﬁcation and management of ADT-related
cardiometabolic risk. Nevertheless, cardiometabolic risk factors
represent sensitive and speciﬁc biomarkers of ectopic fat
deposition(49), which is an important aetiological factor for the
development of CVD, diabetes and chronic liver disease. Also, if
cardiometabolic risk can be identiﬁed at an early, subclinical
stage, this will increase its amenability and responsiveness to
diet and lifestyle modiﬁcation than at a later stage, when long-
term drug therapies must be invoked.
By comparison with the lifestyle interventions of weight
loss and increased physical activity that are advocated after
prostate cancer treatment in cancer survivors, we have
relatively little evidence to support the clinical efﬁcacy of diet-
ary interventions.
Search strategy and selection criteria for review
A systematic search of published literature was conducted
to retrieve studies that reported on nutrition interventions
(according to WHO deﬁnition) or detailed dietary intake after
the diagnosis of prostate cancer, as well as reported cardio-
metabolic risk factors and/or sarcopenia. No restriction was
placed on study design or duration of follow-up. Only studies
reported in English were included from the following electronic
databases: the Cochrane Library, PubMed, MEDLINE, EMBASE
and CINAHL. The Index/MeSH (Medical Subject Heading)
‘prostate cancer’ was combined with terms associated
with nutrition interventions and cardiometabolic risk factors
(metabolic syndrome, body fat distribution, body mass index,
abdominal obesity, morbid obesity, waist circumference, skin-
fold thickness, waist-hip ratio, hypertension, dyslipidaemia,
insulin resistance, hyperglycaemia, blood pressure, cholesterol,
diabetes, dysglycaemia, sarcopenia). Additional search strings
were constructed using key word terms. All searches were
conducted between February and March 2016 and retrieved
1593 published articles since 1 January 2000.
Future strategies for the dietary treatment of androgen
deprivation therapy-induced cardiometabolic risk
Despite similarities between cardiometabolic risk in classic MetS
and that induced by ADT, the rapid onset, and distinct and
highly variable expression of characteristics in the latter,
necessitates a unique and personalised dietary approach. This
will require application of the evidence-based effects of diet
on ADT-related cardiometabolic risk. However, diet and life-
style strategies to treat metabolic complications of ADT have
predominantly focused on the role of exercise in preference to
diet. When the role of diet has been addressed, the quality and
detail of information on the interventions have ranged from
general healthy eating advice, to more prescriptive guidelines
based on the dietary modiﬁcation of cardiovascular risk, using
for example the Adult Treatment Panel III (ATP-III) dietary
guidelines(50). The outcome of dietary interventions reported to
date has often been poorly described and multi-modal, making
it difﬁcult to compare and assimilate results for the design of
future dietary interventions (Table 2). In the absence of such
data, it would seem prudent to adopt an approach based on the
existing evidence for the efﬁcacy of diet on cardiometabolic risk
factors in classic MetS. This approach could then be coupled
with the concept of personalised nutrition, which is based on
the premise that greater improvements in cardiometabolic
health can be achieved by the tailoring of dietary modiﬁcations
to the cardiometabolic risk proﬁle of an individual or, more
realistically, group of individuals. In this respect, the co-
existence of classic obesity or metabolic obesity, with or with-
out sarcopenia, represent key phenotypic differences for the
formulation of an individualised dietary prescription to manage
and reduce ADT-related cardiometabolic risk. This approach
would provide a more consistent, and evidence-based strategy
than many current practices.
Current evidence for the nutritional management of
cardiometabolic risk factors
It is important to emphasise that the nutritional management of
cardiometabolic risk does not strictly include the treatment of
raised serum LDL-cholesterol. While the latter is an established
risk factor for CVD that is associated with increased body
weight, obesity and ADT, and is often classiﬁed as a cardio-
metabolic risk factor, its metabolic origins are distinct from the
classic cardiometabolic risk factors described above. With the
exception of the shared beneﬁts of weight loss, the nutritional
management of elevated serum LDL-cholesterol is also distinct
from the management of cardiometabolic risk, and delivered via
application of the well-documented Portfolio Diet(51,52), which
includes weight loss, if appropriate, the replacement of SFA,
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Fig. 3. Relative proportions of stored body fat in visceral adipose tissue (VAT)
and subcutaneous adipose tissue (SAT), and potential partitioning (arrows) of
stored body fat between VAT, SAT, ectopic sites (for example, liver) and skeletal
muscle (///) in classic metabolic syndrome (MetS) and androgen deprivation
therapy (ADT).
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plant sterols, soya protein, viscous ﬁbres and nuts alongside
regular clinic visits. This combined dietary approach has
been shown to lower LDL-cholesterol more effectively than a
low-saturated fat diet alone(52).
In general, diets that restrict the intake of food energy to
achieve weight loss have proven efﬁcacy in improving
cardiometabolic risk factors in overweight and obese indivi-
duals, primarily by reducing total body fat(53,54). Because body
composition is difﬁcult to assess without high-resolution
imaging techniques, anthropometric measures of BMI, waist
circumference and waist:hip ratio are often used as proxies.
Prescriptive targets for weight reduction include a sufﬁcient
weight loss to achieve a BMI of 25 kg/m2 for the improvement
of hypertension(55), and a BMI of between 21 and 23 kg/m2 for
reducing prostate cancer aggression(56) and an energy restric-
tion of 600 kcal (2500 kJ) per d for the management of
obesity(57). Energy restriction can be achieved by the mani-
pulation of portion size and/or energy density of food, and by
altering behaviour in ways that suppress appetite, hunger and
promote satiety, as for example energy loading early in the
day(58), maintaining an adequate quantity and quality of
sleep(59), by fasting(60) and through meal replacement(61).
Humans have adapted to a pattern of dietary intake in
developed societies that provides ready and regular access to
high-energy-dense foods, which over time will inevitably con-
tribute to weight gain and obesity. This pattern of food intake is
in complete discord with our innate physiology that is designed
to withstand prolonged periods of fasting in an environment
where food is frequently unavailable(62). The unavoidable
imposition of time-restricted feeding or intermittent fasting in an
environment where food is not readily available, but weight
gain and obesity are rare, provides persuasive evidence for the
potential of fasting to improve cardiometabolic health. While
there is, as yet, no convincing evidence to show that time-
restricted feeding or intermittent fasting is more effective than
constant energy restriction in promoting weight loss, there are
data to suggest the former may confer additional beneﬁts in
terms of reducing cardiometabolic risk factors, above and
beyond its impact on weight loss(63,64). In a randomised trial,
the timing of food intake was shown to make an impact upon
cardiometabolic risk factors in young women, in whom insulin
resistance and fasting insulin were signiﬁcantly better in those
who undertook an intermittent energy-restricted dietary pattern,
compared with those who continually restricted dietary
intake(64). Moreover, various fasting practices have been
associated with increased dietary compliance, presumably as a
favoured option for those unwilling to restrict food intake on a
daily basis(65).
For individuals who express increased cardiometabolic risk,
but who are neither overweight nor obese, a condition often
referred to as ‘metabolic obesity’, restricting food energy would
be inappropriate and unethical. There is convincing evidence to
suggest that the origin of cardiometabolic risk in metabolic and
classic obesity arises from increased VAT and excess ectopic fat
in key metabolic tissues, such as the liver, pancreas, heart and
skeletal muscle(66). There are also reports that these depots of
VAT and ectopic fat are reducible by energy-restricted weight
loss and by manipulating the quality of dietary macronutrients.
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The latter is addressed in a review by Abete et al.(61) that
highlights the importance of personalising diets with a speciﬁc
macronutrient ratio (30% protein, 40% low-glycaemic index
(GI) carbohydrates, high amounts of MUFA and n-3 fatty acids)
as well as ﬁbre, isoﬂavones, Ca and antioxidants).
Dietary fat
While much of the emphasis of replacing SFA with PUFA and/or
MUFA is rightfully focused on reducing serum LDL, the
exchange of dietary SFA for PUFA also produces favourable
effects in lowering VAT and liver fat, and on vascular func-
tion(67). In contrast to the established effects of weight loss and
physical exercise on increasing insulin sensitivity, there is no
deﬁnitive evidence to show that isoenergetic changes in diet
produce the same effect. While this applies speciﬁcally to the
replacement of SFA with unsaturated fatty acids(68), a reduction
in VAT following the replacement of SFA with unsaturated fatty
acids would be expected to reduce insulin resistance in this
tissue. Similarly, although the increased intake of long-chain n-3
fatty acids in supplemental doses (1–3 g/d) from puriﬁed
marine sources has no impact on insulin sensitivity, these fatty
acids exert favourable effects on cardiometabolic risk by reducing
serum TAG in the postprandial and post-absorptive phases,
improving vascular function, and lowering biomarkers of low-
grade inﬂammation and blood pressure(69). The cell membranes
of hepatocytes taken from patients with NAFLD have also been
shown to be relatively deﬁcient in long-chain n-3 PUFA and,
conversely, rich in SFA(70). Interestingly, supplements of long-
chain n-3 PUFA are effective in reducing liver fat in NAFLD(71)
which may explain, in part, how these fatty acids produce
beneﬁcial effects on cardiometabolic risk factors.
Dietary carbohydrate
Three ways in which dietary carbohydrates can affect cardio-
metabolic risk factors are via their glycaemic properties, content
of free sugars, and indigestible dietary ﬁbre. GI describes the
rate and extent at which carbohydrate-rich foods raise serum
glucose, and concomitantly insulin, relative to a pure glucose
control. High-GI foods have been linked to obesity and
increased cardiometabolic risk(72). Although there have been
various attempts to list GI on food products, GI is determined
by numerous physiochemical factors that complicate its
measurement and interpretation, and have confounded its
practical application in human dietetics and nutrition. Free
sugars, formally known as non-milk extrinsic sugars, are sugars
added to sweeten foods and include sucrose, a disaccharide of
the monosaccharides glucose and fructose, and fructose. Free
sugars have been shown to make a signiﬁcant contribution to
energy intake in populations, and are thus implicated in the
development of obesity(73), though other more recent data
indicate that dietary fat over a mean range of intakes makes a
greater contribution to body weight(74). High intakes of free
sugars in excess of 20% total energy have been shown to
increase VAT and ectopic fat in the liver, and produce marked
effects on cardiometabolic risk factors(75). Sugar-sweetened
beverages have been identiﬁed as one of the main perpetrators
for the delivery of such high intake of free sugars(76), and thus
potentially adverse metabolic effects, most notably in children
and adolescents. However, the mean intake of free sugars in
adult populations is well below this level of intake, and shows
no signiﬁcant association with the risk of CVD mortality until
free sugars reach about 25% of total energy intake(77). Soluble
and insoluble dietary ﬁbres from vegetable and cereal sources
have been shown to exert favourable and pronounced effects
on cardiometabolic risk factors(78). While the underlying
mechanisms for these beneﬁcial effects of dietary ﬁbre are not
entirely clear, they may involve inﬂuences on the absorption of
nutrients and gut microbiota that are independent of changes in
body weight, and promotion of weight loss via the displace-
ment of absorbable energy from dietary fat and carbohydrates.
Dietary protein
The impact of dietary protein on cardiometabolic risk may be
mediated to a variable extent by its ability to counteract the
adverse metabolic effects of sarcopenia, primarily by reducing
anabolic resistance in skeletal muscle(79). Since it is clear
that the expression of cardiometabolic risk is enhanced in the
presence of sarcopenia, a strategic priority must be to ensure an
adequate intake of total protein, and then to consider the
quality and time of ingestion of protein in relation to its anabolic
effects on skeletal muscle(80).
Salt and alcohol
The adverse consequences of salt and alcohol are largely centred
on their effects in raising blood pressure. Accepted recommen-
dations for the prevention and treatment of hypertension are to
lower salt intake to achieve 1·5g Na/d and moderation of alcohol
intake (two units/d for men; one unit/d for women)(55).
Dietary patterns
There is emerging evidence that the most effective dietary stra-
tegies for reducing risk and mortality from multifactorial CVD are
based on the modiﬁcation of multiple dietary components within
a dietary pattern. Examples of such dietary patterns include
variants of the Dietary Approaches to Stop Hypertension (DASH)
diet(81,82) (rich in fruits and vegetables (eight to ten servings/d),
rich in low-fat dairy products (two to three servings/d), and
a reduction in saturated fat and cholesterol and K intake
(120mmol/d)), and variants of the Mediterranean diet, as tested in
the PREDIMED (Prevención con Dieta Mediterránea) study(83).
While these interventions were not speciﬁcally designed to lower
cardiometabolic risk, it is reasonable to assume that since cardio-
metabolic risk has a multifactorial aetiology, it will be more
responsive to multiple dietary changes within an altered dietary
pattern. Focusing on whole foods and dietary patterns rather than
single nutrients also reﬂects the way in which free-living humans
consume nutrients and measure their dietary intake. This
approach has been embraced recently by the new dietary
guidelines in the Netherlands, which are based entirely on
manipulating the intake of whole foods(84).
The Mediterranean diet has become renowned as a dietary
pattern associated with the prevention of CVD, which has been
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successfully tested in the PREDIMED study. The key principles
of this dietary pattern are a largely plant-based diet, featuring
fruit, vegetables, whole grains and nuts with moderate amounts
of oily ﬁsh, olive oil and nuts, and smaller quantities of trans-
fatty acids and SFA, red meat and processed and reﬁned foods.
The PREDIMED study intervened in men at increased risk of
CVD with two variants of the Mediterranean diet supplemented
with either extra-virgin olive oil (four tablespoons/d) or mixed
nuts (≥3 servings/week) against a control group who were
advised to lower their intake of dietary fat. After 4·8 years, the
oil- and nut-supplemented diets reduced the risk of cardiovas-
cular events by 30 and 28%, respectively, relative to the control.
A personalised, phenotypic dietary approach for the
treatment of androgen deprivation therapy-related
cardiometabolic risk
As previously described (Table 1), patients on ADT express a
variable combination of drug-induced cardiometabolic risk factors.
These can be subdivided into four risk categories or phenotypes,
each of which will require different dietary priorities (Table 3).
Increased cardiometabolic risk can exist in the absence of a
BMI in excess of 30 kg/m2 (metabolic ‘obesity’), but the concept
of metabolic ‘healthy’ obesity has recently been challenged
as a non-entity because of conﬂicting evidence for the presence
of cardiometabolic risk in this condition(85). This provides
supporting rationale for placing all patients on ADT on a
cardioprotective diet, which whilst having no negative effects
on health, will be effective in the management of insulin
resistance, dyslipidaemia, mild hypertension and vascular
dysfunction. Superimposed on this is the priority to promote
weight loss in overweight or obese patients, and the need to
consider the preservation of muscle mass, if the patients shows
signs of sarcopenia. The guidelines described in Table 4 were
derived from the compilation of various dietary patterns which
have been shown to reduce CVD risk.
Management of weight and fat distribution
Energy restriction is required to promote weight loss in ADT
patients who are overweight or obese (600 kcal (2500 kJ)/d
reduction advised by the National Institute for Health and Care
Excellence (NICE)). While weight reduction alone appears to be
achievable with a daily energy restriction, there is emerging
evidence to suggest that additional improvements in insulin
resistance and lean mass retention can be achieved through
intermittent energy restriction(63,64).
Sarcopenia
Limited studies have investigated skeletal muscle mass and
metabolism in patients on ADT. It has been suggested that
promyogenic drugs and myokines may be required to reduce
the risk of sarcopenia and frailty in patients on ADT(86). There
is, as yet, no convincing evidence to support the efﬁcacy of
lifestyle interventions (nutrition and exercise interventions) as a
means for attenuating muscle loss in patients on ADT. It is
therefore reasonable to suggest that patients on ADT who show
signs of muscle weakness follow similar therapeutic strategies
to those who are at risk of muscle wastage, but not on ADT,
such as regular protein intake and consumption of speciﬁc
amino acids.
Weight-loss programmes tend to promote a loss of both fat
mass and fat-free mass. A study of 275 men and women in the
USA concluded that men decreasing their body weight by 10%
should expect 35–40% of the weight loss to be fat-free mass(87).
To prevent this loss of muscle in overweight and obese patients
with sarcopenia, many studies have examined how weight-loss
programmes can be adapted to preserve lean tissue. Increasing
protein intake to above 0·9 g/kg per d was shown to be inef-
fective in preserving muscle mass in obese adults(88). In con-
trast, a reduction in energy intake of 500 kcal (2100 kJ)/d with
the consumption of whey-protein supplement (20 g protein/d)
was shown to promote a signiﬁcant loss of fat mass whilst
preserving fat-free mass, as compared with a control group in
obese adults(89). The synthesis of myoﬁbrillar protein was also
shown to be stimulated to a signiﬁcantly greater extent in a
weight-reducing diet that was supplemented with isolated whey
protein (1·3± 0·1 g protein/kg per d) as compared with soya or
carbohydrate(90). Moreover, obese patients following a 600 kcal
(2500 kJ)/d energy reduction, resistance training programme
and consuming a supplement containing whey protein, leucine
and vitamin D containing 21 g protein (equating to an overall
protein intake of 1·11± 0·28 g protein/kg per d) preserved
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Table 3. Cardiometabolic risk factors and dietary priorities in different physical phenotypes resulting from androgen deprivation therapy
Phenotype
Normal weight and no
sign of muscle wastage
Normal weight and muscle
wastage
Overweight and no sign of
muscle wastage Overweight and muscle wastage
Cardiometabolic risks
factors
Insulin resistance
Dyslipidaemia
Mild hypertension
Vascular dysfunction
Ectopic fat
Insulin resistance
Dyslipidaemia
Mild hypertension
Vascular dysfunction
Ectopic fat
Sarcopenia
Insulin resistance
Dyslipidaemia
Mild hypertension
Vascular dysfunction
Ectopic fat
Increased SAT leading to higher
risk of cardiovascular events
Insulin resistance
Dyslipidaemia
Mild hypertension
Vascular dysfunction
Ectopic fat
Sarcopenia
Increased SAT leading to higher
risk of cardiovascular events
Dietary priorities Prevention of CVD Prevention of CVD
Prevention of
muscle loss
Prevention of CVD
Weight reduction
Prevention of CVD
Prevention of muscle loss
Weight reduction
SAT, subcutaneous adipose tissue.
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appendicular muscle mass in comparison with a control group
who did not consume a protein supplement(91).
There is evidence to suggest that despite the similar effects of
daily and intermittent energy restriction on weight loss, a higher
percentage of lean mass may be preserved when undertaking
intermittent energy restriction in the form of ‘feeding’ and
‘fasting’ days(63).
The timing of daily protein intake may also be important in
this respect. The 24 h mixed muscle protein fractional synthesis
rate was shown to be signiﬁcantly higher when protein was
evenly distributed throughout the day, as compared with
skewing intake towards the evening meal(80). A list of putative
dietary factors with potential to prevent sarcopenia that results
from advancing age includes protein, vitamin D, antioxidants,
long-chain PUFA and dietary patterns(92).
Psychological and clinical considerations
As with any long-term diet and lifestyle modiﬁcation, the ability
for an individual to sustain change relies partly on the conscious
and subconscious psychological strategies employed throughout
the intervention. Michie et al.(93) have generated a framework of
psychological techniques, used within the realms of diet and
exercise regimens, and various behaviour change techniques to
help individuals modify their behaviours. The latter includes, but
is not limited to, goal setting, action planning, barrier identiﬁcation
and problem solving. Lifestyle interventions should not disregard
the importance of considering behaviour change techniques
which can greatly improve compliance and make an impact on
outcomes. Abete et al.(61) also highlight the relevance of investi-
gating the intrinsic and extrinsic determining factors of dietary
intake to aid compliance in promoting weight loss.
Dietitians and nutrition professionals often receive referrals for
patients with cancer who require nutrition support for weight loss
as a result of various cancer treatments. Men who are struggling
with weight gain and increased cardiovascular risk may be over-
looked because weight gain during cancer is perhaps not expected
and not monitored in these patients. The holistic clinical care of a
patient’s health can also be diminished when individual elements
of their condition are managed by different individuals. There is a
need to highlight these issues in the service currently provided
to patients with prostate cancer, and to generate guidelines that
include referral criteria for various healthcare professionals who
can advise on lifestyle changes that could reduce risk of CVD.
Summary and conclusions
ADT is highly effective in reducing mortality from prostate
cancer, but certain forms of this therapy, most notably GnRH
agonists, induce cardiometabolic abnormalities that can lead to
premature cardiac events. While ADT-induced cardiometabolic
risk is similar to that found in classic MetS, it is distinct in having
a single underlying cause of testosterone deﬁciency, a more
rapid onset, and being characterised by an accumulation of
SAT, and sarcopenia and sarcopenic obesity.
Cardiometabolic risk can be reduced through energy
restriction to promote weight loss, and by manipulating the
composition of macronutrients, chieﬂy fat and carbohydrate, to
target speciﬁc metabolic risk factors. Existing evidence for the
beneﬁcial role of diet in the prevention of ADT-related cardio-
metabolic risk is scant. Future treatment strategies should con-
sider adopting an evidence-based approach with a personalised
strategy that tailors dietary modiﬁcation to the risk phenotype of
the patient. Nutritional assessment should include consideration
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Table 4. Dietary guidelines for the treatment of androgen deprivation therapy-related cardiometabolic risk
Area Guidelines
Fruit and vegetables Five to ten portions of fruit and vegetables per d (all varieties such as fresh, frozen, canned) including 10 g of viscous fibres per
1000 kcal (4184 kJ) from foods such as psyllium, okra and aubergine. Try to include tomato-based sauces containing onion,
garlic and olive oil at least twice per week
High-protein foods As far as possible, try to split protein intake evenly throughout the day (20–30 g of high-quality protein is suggested per meal
containing 2·5–2·8 g leucine where possible). Plant-based protein such as legumes, nuts and seeds should each be
consumed at least three times per week. 23 g of almonds per 1000 kcal (4184 kJ) consumed may lower cholesterol. Soya
protein should also be consumed regularly in similar quantities to almonds. Two eggs provide protein and essential amino
acids so should also be consumed regularly. Fish, especially oily fish, and seafood should be consumed at least three times
per week. White meat should be chosen over red meat where possible; however, red meat in quantities of less than 490 g per
week can still be part of a balanced diet providing it is lean and red and processed meat is not eaten on a daily basis
Fats Fats should not contribute more than 27% of daily energy intake and saturated fat intake should be less than 6%. Saturated
fats such as butter, cream, lard and coconut oils should be limited. Spreadable fats should be used on average less than
once per d. Monounsaturated fats such as polyphenol-enriched olive oil should be included in the diet on a daily basis in
quantities of four or more tablespoons
Starchy foods Starchy foods should be mainly whole grains and one should aim to include 10 g of viscous fibres from foods such as oats and
barley per d
Dairy products Dairy products should be restricted to low-fat varieties where possible and depending on weight should be consumed in
quantities of 1·5–2·5 servings per d if weight loss is a goal or 2–3 servings per d if weight maintenance is a goal
Functional foods and
vitamins
1g of plant sterols should be consumed for every 1000 kcal (4184 kJ)
Foods containing vitamin D such as cod liver oil, salmon, sardines, etc. should also be included in the diet regularly
Limited foods Commercial bakery goods and sweets should be limited and fat-free or low-fat should be chosen where possible
Sugar should also be swapped to sweetener when applicable
Soda drinks should be limited to the equivalent of less than one per d
Alcohol (for habitual drinkers only) should not exceed two drinks (preferably wine with meals) per d and alcohol-free days should
be observed
Caffeine consumption should be discussed with the general practitioner
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of the level to which a patient adheres to the Mediterranean
diet, the quantity, quality and timing of protein intake, overall
energy content and GI, while ensuring that World Cancer
Research Fund guidelines are being met. We await the outcome
of adequately powered RCT to establish if these dietary
modiﬁcations will be successful in ameliorating ADT-related
cardiometabolic risk.
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